Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NLP-328
- Development stage
- Preclinical
- Lead developer
- NovaLead Pharma
- Modality
- Small Molecules
- Administration
- Unknown
01
Overview
NLP-328 is a small molecule drug candidate under development by NovaLead Pharma. It is being investigated primarily for the treatment of venous leg ulcers (also known as varicose ulcers). The drug is currently in preclinical development and has not yet entered clinical trials. Specific details about its mechanism of action have not been disclosed in public sources, but it is categorized as a small molecule therapy for wound healing indications[1][9].
- Other names
- NLP328NLP-328NLP 328
Beyond the preview
Go deeper on NLP-328.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NLP-328.